EUR/USD 1.17964
-0.086%
Gold 4910.26
-1.116%
Oil 63.930
-0.470%
USD/JPY 157.077
0.129%
GBP/USD 1.36050
-0.346%
GBP/JPY 213.705
-0.195%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
February 5th - Shanghai Henlius Biotech (02696.HK) announced that it has entered into a licensing agreement with Japanese pharmaceutical company Eisai Co., Ltd., under which the company will grant Eisai an exclusive license to commercialize its licensed product Hanszal® (Slulimab injection) in the region and field. Eisai will pay the company an upfront payment of US$75 million, regulatory milestone payments totaling up to US$80.01 million based on the achievement of various regulatory milestones for the licensed product in the region, and commercial sales milestone payments totaling up to US$233.33 million based on the achievement of annual net sales of the licensed product in the region, plus royalties calculated as a double-digit percentage of the annual net sales of the licensed product in the region.Volkswagen shares fell 3.2%, poised for their biggest one-day drop since September 2025.February 5th - Hengrui Medicine announced that it recently received an Acceptance Notice from the National Medical Products Administration (NMPA) for its marketing authorization application for HR091506 tablets. HR091506 tablets are febuxostat oral sustained-release tablets with pulsatile release characteristics, independently developed by the company using gastric retention formulation technology. The product consists of an immediate-release portion and a delayed-release portion. After oral administration, the immediate-release portion is rapidly released in the stomach to achieve an effective blood drug concentration; the delayed-release portion remains in the stomach for sustained release, aiming to prolong the duration of effective blood drug concentration and improve the rate of uric acid reduction.February 5th – A meeting on financial support for the construction of the Western Land-Sea New Corridor was held in Chongqing on the morning of February 5th. Pan Gongsheng, Secretary of the Party Committee and Governor of the Peoples Bank of China (PBOC), stated that providing financial support for the construction of the Western Land-Sea New Corridor is a crucial responsibility of the PBOC and the financial system. The PBOC will continue to support the accelerated construction of the Western Land-Sea New Corridor, strengthen coordination with provinces (autonomous regions and municipalities) along the corridor, support the continuous construction and development of the financial services and infrastructure system of the Western Land-Sea New Corridor with Chongqing as a hub, promote the interconnection and optimization of financial elements, enrich and develop the financial services and product system, enhance the precision and effectiveness of financial support, coordinate high-level financial opening-up and security, improve the facilitation of cross-border trade settlement and investment and financing along the corridor, optimize cross-border financial services, and better serve the construction of the Western Land-Sea New Corridor and the high-quality development of the western region.Statoil: Starting February 1 this year, it will supply gas to the Dutch gas pipeline network, with an annual supply of up to 500 million cubic meters.

SEC vs Ripple Update Dial-In Details Available for June 7 Conference

Jimmy Khan

Jun 06, 2022 11:59

Ripple and XRP had a busy week. Judge Sarah Netburn set a June 7 conference in response to a May 18 SEC filing and a May 13 Ripple reply.


The May 13 reply came in response to an SEC filing asserting attorney-client privilege shields William Hinman's 2018 speech.


The SEC vs Ripple lawsuit has been in the spotlight this year.

SEC v Ripple Dial-in Option Allows Attendance

James Filan, the defense counsel in SEC v Ripple, posted dial-in data on June 3.


The conference begins at 3pm EST. The tweet states, "USA 877-226-8215 INT 409-207-6982 Code 4713826#."


Stay tuned to @FilanLaw for updates. Calling too early will give you the erroneous code.

The conference's decision might affect SEC v. Ripple and the crypto market.


Hinman said bitcoin and Ethereum aren't securities in 2018.


Ripple Labs filed a compel motion in 2021. Motion demanded SEC speech materials.


Ripple defense lawyer Matthew Solomon objected to the SEC brief, noting that the SEC has filed at least six motions to dispute Ripple's request to compel.


A defense win would allow Ripple Labs to explore the categorization of bitcoin, Ethereum, and other cryptocurrencies.


It remains to be seen if Judge Netburn allows additional SEC filings on the attorney-client privilege.

Tuesday's conference will likely affect XRP.

SEC Case Determined XRP Price

XRP rose 1.82 percent to $0.4023 at press time.


XRP's early morning high was $0.4033.


First Major Resistance Level was $0.3998.

INDICATORS

XRP must avoid the First Major Resistance Level and $0.3946 to retarget $0.4046. XRP needs the crypto market to avoid sub-$0.40.

XRP should challenge $0.41 barrier if it rallies. Third major resistance is $0.4146.


A break below First Major Resistance would result in First Major Support at $0.3898.


XRP should avoid sub-$0.3850 barring another lengthy sell-off. Second major support is $0.3846.


EMAs and 4-hourly candlestick chart are bearish. XRP is below the 100-day EMA at $0.4102. 50-day EMA narrowed to 100-day EMA this morning. 100-day EMA flattened on 200-day EMA, XRP up.


A break of the 100-day EMA would support $0.45. SEC v Ripple will determine the week's direction.


Suggestion